FDA Expands Arexvy RSV Vaccine Approval to Adults Aged 18-49 at Increased Risk
GSK sits 68% above its 52-week low of $32.38.
Summary
GSK's RSV vaccine, Arexvy, received expanded US FDA approval for adults aged 18-49 at increased risk, significantly growing its potential market.
Key Events · Product Development and Regulatory · GSK
-
Expanded FDA Approval for Arexvy
The US Food and Drug Administration (FDA) has expanded the approved age indication for GSK's Respiratory Syncytial Virus (RSV) vaccine, Arexvy, to include adults aged 18 to 49 years who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV.
-
Significant Market Opportunity
This expansion targets an estimated 21 million adults under 50 in the US who have at least one risk factor for severe RSV infection, representing a substantial new patient population for the vaccine.
-
Strategic Growth for GSK
The decision is supported by positive Phase IIIb trial data and aligns with GSK's strategy to expand RSV prevention to broader adult populations, reinforcing its position in the vaccine market and contributing to long-term growth objectives.
Analysis · GSK · Life Sciences
The US FDA's expanded approval for Arexvy significantly broadens the vaccine's addressable market to include adults aged 18-49 who are at increased risk for severe RSV disease. This decision opens up a substantial new patient population, estimated at 21 million adults in the US, which is a major commercial opportunity for GSK's key vaccine. This regulatory win reinforces GSK's leadership in the vaccine market and is expected to contribute positively to future revenue growth for Arexvy, easing pressure on the healthcare system by preventing severe RSV cases in a younger, at-risk demographic.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $54.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $108.5B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.